“…Most of them (n = 17) were conducted in the USA, while five studies were carried out in the Netherlands [62,65,66,71,78], two in Canada [67,79], two in Australia [66,68], one in the United Kingdom [69], one in Portugal [56], one in France [57], and another one in Japan [63]. Twenty-one records focused only on hereditary breast and ovarian cancer syndrome (HBOC); three focused on hereditary non-polyposis colorectal cancer syndrome (HNPCC) [59,63,80]; three studies comprised a sample of both HBOC and HNPCC pathogenic variant carriers [65,66,81]; one study included HNPCC, HBOC, and hereditary diffuse gastric cancer syndrome (HDGC) pathogenic variant carriers [56]; and one study regarded Familial Adenomatous Polyposis [71]. The sample size varied from a minimum of 17 participants (cumulative between pathogenic variant carriers and their family members) [79] to a maximum of 272 pathogenic variant carriers, only [65,66].…”